Report for Q1 2026
Filed with SSE · · 12 pages · Chinese
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Renewing Engagement of Accounting Firm
- Announcement on Receiving the Clinical Trial Approval Notice for Qingshen Tongluo Granules
- Announcement on Appointment of Deputy General Manager
- Announcement on Receiving the Clinical Trial Approval Notice for Heihuang Chizhu Granules
Later from Jiangsu Kanion Pharmaceutical
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit
- Announcement on Cancellation of Repurchased Shares and Notification to Creditors
- Announcement on Progress in Repurchasing Shares through Call Auction
- Announcement on Inclusion of Certain Pharmaceutical Products of the Company in the National Essential Medicines List
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical